Literature DB >> 17534728

Seroprevalence of varicella antibodies among pregnant women in Lyon-France.

M Saadatian-Elahi1, Y Mekki, C Del Signore, B Lina, T Derrough, E Caulin, J Thierry, P Vanhems.   

Abstract

The purpose of the study was to calculate the seroprevalence of immunity to the varicella-zoster virus (VZV) infection and to evaluate the positive predictive value (PPV) and the negative predictive value (NPV) of the self-reported history of VZV infection in pregnant women. A cross sectional study was conducted in 18 private medical analysis laboratories. Information on socio-demographic characteristics and past history of varicella or zoster were collected using a questionnaire. Blood samples were obtained to determine the serological levels of past exposure to VZV. Overall, 486 pregnant women were recruited. The seroprevalence of VZV antibodies was 98.8%. Six women were seronegative, of whom four were primiparous. The PPV was high (99.5%) while the NPV was only 10.3%. The PPV is a reliable marker of prior VZV infection. In contrast, a negative history does not predict lack of immunity and should be completed by serological analysis which might be introduced to routine antenatal blood tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534728     DOI: 10.1007/s10654-007-9136-z

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   12.434


  21 in total

Review 1.  [Chickenpox in pregnancy].

Authors:  A Berrebi; C Assouline; J M Ayoubi; O Parant; J Icart
Journal:  Arch Pediatr       Date:  1998-01       Impact factor: 1.180

2.  Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes.

Authors:  L Salleras; A Domínguez; J Vidal; P Plans; M Salleras; J L Taberner
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

3.  Seroprevalence of varicella in the French population.

Authors:  Babak Khoshnood; Monique Debruyne; Florian Lançon; Corinne Emery; Francis Fagnani; Isabelle Durand; Daniel Floret
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

4.  Correlation of a reported history of chickenpox with seropositive immunity in pregnant women.

Authors:  David M Plourd; Katherine Austin
Journal:  J Reprod Med       Date:  2005-10       Impact factor: 0.142

5.  Varicella-zoster virus infections in pregnancy.

Authors:  A Sauerbrei
Journal:  Intervirology       Date:  1998       Impact factor: 1.763

6.  Susceptibility to infectious rash illness in pregnant women from diverse geographical regions.

Authors:  S J Knowles; K Grundy; I Cahill; M T Cafferkey
Journal:  Commun Dis Public Health       Date:  2004-12

7.  Reported exposure to chickenpox: a predictor of positive anti-varicella-zoster antibodies in parturient women.

Authors:  N Linder; A Ferber; U Kopilov; Z Smetana; A Barzilai; E Mendelson; L Sirota
Journal:  Fetal Diagn Ther       Date:  2001 Nov-Dec       Impact factor: 2.587

8.  Seroprevalence of varicella-zoster virus in the German population.

Authors:  P Wutzler; I Färber; S Wagenpfeil; H Bisanz; A Tischer
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

Review 9.  Evaluation of varicella immune status in an obstetric population in relation to place of birth.

Authors:  Jay M Goldberg; Harry K Ziel; Raoul Burchette
Journal:  Am J Perinatol       Date:  2002-10       Impact factor: 1.862

10.  Outcome after maternal varicella infection in the first 20 weeks of pregnancy.

Authors:  A L Pastuszak; M Levy; B Schick; C Zuber; M Feldkamp; J Gladstone; F Bar-Levy; E Jackson; A Donnenfeld; W Meschino
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

View more
  14 in total

1.  Recent trends in publications in the European Journal of Epidemiology.

Authors:  Albert Hofman
Journal:  Eur J Epidemiol       Date:  2008       Impact factor: 8.082

Review 2.  Epidemiology and factors influencing varicella infections in tropical countries including Sri Lanka.

Authors:  S W P Lakmini Daulagala; Faseeha Noordeen
Journal:  Virusdisease       Date:  2018-07-06

3.  Prevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age.

Authors:  Didier Pinquier; Arnaud Gagneur; Laurent Balu; Olivier Brissaud; Christèle Gras Le Guen; Isabelle Hau-Rainsard; Olivier Mory; Georges Picherot; Loïc De Pontual; Jean-Louis Stephan; Peter Maple; Judith Breuer; Marie Aubert; Evelyne Caulin; Claudine Sana; Pierre Pradat; Benoît Soubeyrand; Philippe Reinert
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

Review 4.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

5.  Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Authors:  Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

Review 6.  Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.

Authors:  Benson Ogunjimi; Pierre Van Damme; Philippe Beutels
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

7.  Seroprevalence of varicella-zoster virus among pregnant women in two teaching hospitals, Tehran, Iran.

Authors:  Mahshid Talebi-Taher; Maryam Kashanian; Katayoon Khalili
Journal:  Iran J Microbiol       Date:  2014-02

8.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

9.  Herpes virus seroepidemiology in the adult Swedish population.

Authors:  Jan Olsson; Eloise Kok; Rolf Adolfsson; Hugo Lövheim; Fredrik Elgh
Journal:  Immun Ageing       Date:  2017-05-10       Impact factor: 6.400

10.  Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010-2011.

Authors:  Dominique Baratin; Corinne Del Signore; Jacques Thierry; Evelyne Caulin; Philippe Vanhems
Journal:  BMC Public Health       Date:  2012-11-01       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.